Sanofi (SAN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Sanofi is a healthcare company that researches, develops, manufactures and markets a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; womens health; and vitamins, minerals and supplements. The R&D efforts of Sanofi include working on combination drugs to increase the effectiveness of treatments and advancing the formulation of new biologics to produce medicines with precision. It has operations across Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

Sanofi (SAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 10
List of Figures 15
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16
Sanofi, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 17
Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18
Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 19
Sanofi, Medical Devices Deals, 2012 to YTD 2018 21
Sanofi, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 22
Sanofi, Pharmaceuticals & Healthcare, Deal Details 36
Asset Purchase 36
Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 36
Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 37
Genzyme Acquires Caprelsa from AstraZeneca 39
Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 40
Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 41
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For US$98.5 Million 42
Sanofi To Acquire Generic Drugs Rights From Medreich India 43
Venture Financing 44
Thermalin Raises Funds through First Tranche of Series A Preferred Financing 44
True North Therapeutics Raises USD45 Million in Series D Financing 45
True North Therapeutics Raises USD40 Million in Series C Financing 46
Portal Instruments Raises USD25 Million in Series B Financing 48
MyoKardia Raises USD46 Million in Series B Financing 49
True North Therapeutics Raises USD35 Million in Series B Financing 50
Portal Instruments Raises USD11 Million in Series A Venture Financing 51
True North Therapeutics Raises USD22 Million in Series A Venture Financing 52
Edimer Pharma Raises US$18 Million In Series B Financing 54
Ultragenyx Pharma Raises US$75 Million In Series B Financing 56
Kahr Medical To Raise US$2.5 Million In Venture Financing 58
Warp Drive Bio Raises US$75 Million In Series A Venture Financing 60
Private Equity 61
Advent International to Acquire Zentiva from Sanofi for USD2.37 Billion 61
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 63
Sanofi Plans to Sell Portfolio of Drugs 65
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 66
Partnerships 67
Ablynx Exercises Option for Licensing Agreement with Vectura 67
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 68
Evotec Enters into R&D Agreement with Sanofi 69
Translate Bio to Enter into Agreement with Sanofi Pasteur 70
Innovative Targeting Solutions Enters into Research Agreement with Sanofi 71
Applied BioMath Enters into Partnership with Sanofi for Systems Pharmacology Modeling 72
AnaBios and Sanofi Enter into Agreement 73
Iontas Enters into Agreement with Sanofi 74
Alnylam Pharma and Sanofi to Enter into Agreement 75
Sanofi to Form Partnership with Groupe Saidal and Pasteur Institute of Algeria 76
Berg Enters into Research Agreement with Sanofi 77
Applied BioMath Enters into Partnership with Sanofi 78
Sanofi Enters into Agreement with Max Delbruck Center, Charite and Berlin Institute of Health 79
Thermalin Enters into Partnership with Sanofi 80
Bioverativ Enters into Research Agreement with Bicycle Therapeutics 81
Axxam Enters into Research Agreement with Sanofi 82
AbCellera Biologics Enters into Partnership with Sanofi Pasteur 83
Ex Scientia Enters into Research and Option Agreement with Sanofi 84
Sanofi Enters into Research Agreement with Exscientia 85
Sanofi Enters into Co-Development Agreement with MedImmune 86
Sanofi Enters into Co-Promotion Agreement with Yakult Honsha 87
Enteris BioPharma Enters into Agreement with Sanofi 88
Sanofi Enters into Agreement with JHL Biotech 89
Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 90
Mymetics Enters into Research Agreement with Sanofi 91
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 92
Myriad Enters into Agreement with Sanofi 93
Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 94
Protein Sciences Enters into Agreement with Biomedical Advanced Research and Development Authority 95
Sanofi Pasteur Expands R&D Agreement with Walter Reed Army Institute of Research and Bio Manguinhos and Fiocruz 96
Sanofi Enters into Co-Development Agreement with Joslin Diabetes Center 97
Sanofi Enters into Research Agreement with Ksilink 98
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 99
Recursion Pharma Enters into Research Agreement with Genzyme 100
Hummingbird Bioscience Enters into Partnership with Sanofi 101
Protein Sciences Enters into Co-Development Agreement with Sinergium Biotech and Mundo Sano 102
Sanofi Enters into Research Agreement with DiCE Molecules 103
Sanofi Enters into Drug Discovery Agreement with University of Tokyo 104
Sanofi and Juvenile Diabetes Research Foundation Partner with Four Research Organizations 105
Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 107
X-Chem Enters into Agreement with Sanofi 108
Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 109
Sanofi Pasteur Enters into Partnership with Infectious Disease Research Institute 110
PeptiDream Enters into Discovery Agreement with Sanofi 111
Evotec Enters into Research Agreement with Sanofi 112
Regeneron Pharma Amends Co-Development Agreement with Sanofi 113
Sanofi-Aventis Extends Agreement with Medicines For Malaria Venture 115
Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 116
Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 117
NeuroVive Pharma Enters into Co-Development Agreement with Sanofi 118
Ablynx Enters into Research Agreement with Genzyme 119
Innate Pharma Enters into Agreement with Sanofi for Next Generation Antibody-Drug Conjugates 120
VBI Vaccines Enters into Research Agreement with Sanofi Pasteur 121
Schrodinger Enters into Agreement with Sanofi 122
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 123
Regeneron Pharma Amends Co-Development Agreement with Sanofi 124
Voyager Therapeutics Enters into Development Agreement with Genzyme 125
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 126
Sanofi Enters into Research Agreement with Vect-Horus 127
Catalent Pharma Enters into Co-Development Agreement with Sanofi-Aventis 128
Evotec to Enter into Co-Development Agreement with Sanofi 129
Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 131
Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 132
Apollo Hospitals Plans to Form Joint Venture with Sanofi 133
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 134
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 135
Sanofi Extends its Co-Development Agreement with MyoKardia 136
Sanofi Enters into Distribution Agreement with Emcure for Oncology Drugs 137
Sanofi Enters into Co-Development Agreement with Medtronic 138
Sanofi Enters into Drug Discovery Agreement with CQDM 139
Dubai Investments to Enter into Agreement with Sanofi to Promote Generics 140
Genzyme Enters Into Research Agreement With Cleveland Clinic 141
Taiwan Liposome and Ablynx Enter into Research Agreement 142
Sanofi Enters Into Agreement With UCB For Drug Discovery 143
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 144
Smartox Biotech Enters Into Research Agreement With Sanofi For Drug Discovery 146
Sanofi Pasteur Enters into Agreement with University of Melbourne to Develop Human Vaccines 147
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 148
Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 149
Gubra Enters into Research Collaboration with Sanofi 150
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 151
NextBio Enters Into Agreement With Sanofi For Translational Medicine 152
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 153
Sanofi Pasteur Enters Into Co-Development Agreement With Xiamen University For Universal Flu Vaccine 154
Oncodesign Enters Into Research Agreement With Sanofi 155
Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 156
PharmAbcine Enters Into Research Agreement With Sanofi For Antibody Drug Discovery 157
Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 158
Y-Biologics Expands Agreement with Sanofi 159
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 160
LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea For Zemiglo 161
Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 162
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 163
China State Institute of Pharma Enters Into Research Agreement With Sanofi 164
Sanofi Enters Into Research Agreement With Charite- Universitatsmedizin For Treatment Of Diabetes 165
Sanofi Enters Into Research Agreement With TB Alliance To Advance Treatments For Tuberculosis 166
Sanofi Enters Into Research Agreement With Oncodesign 167
LegoChem Biosciences Enters into Research Agreement with Sanofi 168
Sanofi Enters Into Research Agreement With Brigham and Womens Hospital 169
Regulus Therapeutics Expands Agreement With Sanofi-Aventis 170
Sanofi Forms Joint Venture With Hisamitsu Pharma For OTC Medications 171
Sanofi Enters Into Co-Development Agreement With Joslin Diabetes Center For Novel Diabetes Drugs 172
Sanofi Enters Into Research Agreement With Bioneer 173
Sanofi Enters Into Co-Development Agreement With Alfresa For Antiepileptic Drug 174
Sanofi Enters into Co-Development Agreement with CNRH, INRA, ASL and 3iNature 175
Centre For Genomic Regulation Enters Into Research Agreement With Sanofi 176
Centre de Regulacio Genomica Enters Into Research Agreement With Sanofi 177
Sanofi Pasteur India Enters Into Co-Marketing Agreement With Emcure Pharma For Rabies Vaccine 178
University of California Enters Into Research Agreement With Sanofi 179
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 180
Merger 181
Sanofi Japan and Genzyme Japan Merge 181
Licensing Agreements 182
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 182
Sanofi Pasteur Enters into Licensing Agreement with SK Chemicals 183
Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 184
Sanofi to Enter into Licensing Agreement with Principia Biopharma 185
Sanofi Enters into Licensing Agreement with Ablynx 186
Sanofi Enters into Licensing Agreement with ImmuNext 187
Sanofi Enters into Licensing Agreement with Hanmi Pharma 188
Avanzcare Enters into Licensing Agreement with Protein Sciences 189
uniQure Enters into Licensing Agreement with Protein Sciences 190
Sanofi Enters into Licensing Agreement with Affilogic 191
IXALTIS Enters into Licensing Agreement with Sanofi 192
Orygen Biotecnologia Enters into Licensing Agreement with Protein Sciences for Flublok 193
Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 194
Sanofi Enters into Licensing Agreement with Innate Pharma 195
Novo Nordisk Enters into Licensing Agreement with Ablynx 196
Sanofi Amends Licensing Agreement with Lexicon Pharma 197
Sanofi Enters into Licensing Agreement with BioNTech 199
Sanofi Enters into Licensing Agreement with Ligand Pharma 200
Zai Lab Enters into Licensing Agreement with Sanofi 201
Taisho Pharma Enters into Licensing Agreement with Ablynx 202
Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 203
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 204
Protein Sciences Enters into Licensing Agreement with Liomont for Flublok and Panblok 205
Sanofi Enters into Licensing Agreement with Immune Design 206
CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 207
Sanofi Enters into Licensing Agreement with Eli Lilly for Cialis 208
Oxford BioMedica Amends Licensing Agreement With Sanofi 210
Merck Expands Licensing Agreement with Ablynx 211
Ablynx Enters Into Licensing Agreement With Eddingpharm 213
Regulus Therapeutics Amends Licensing Agreement With Sanofi 215
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 216
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 217
Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 218
Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 219
Sanofi Pasteur Expands Licensing Agreement With Vivalis 220
Sanofi Enters into Licensing Agreement with Warp Drive Bio 221
Sanofi Enters into Licensing Agreement with MAB Discovery 222
Sanofi Enters into Licensing Agreement with Lead Pharma for Autoimmune Diseases 223
ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 224
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 225
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 226
uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 227
Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 228
Sanofi Pasteur Enters Into Licensing Agreement With ORGANOBALANCE For Saccharomyces Cerevisiae 229
Equity Offering 230
Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 230
Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 231
Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 232
Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 233
Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 235
Ablynx Amends Private Placement of Shares 236
Ablynx Raises USD1.05 Million Through Exercise of Warrants 238
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 239
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 240
Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 241
JHL Biotech Raises USD80 Million in Private Placement of Shares 242
Ablynx Raises USD82.6 Million in Private Placement of Shares 243
Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 245
Ablynx Raises USD1.4 Million upon Exercise of Warrants 246
Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 247
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 248
X4 Pharma Spin Off from Sanofi 249
Protein Sciences Raises USD0.6 Million in Private Placement of Shares 250
Ablynx Raises USD57 Million in Private Placement of Shares 251
Regulus Therapeutics Completes Private Placement Of Shares For US$10 Million 253
Protein Sciences Raises USD8.4 Million in Private Placement of Shares 254
Ablynx Completes Private Placement Of Shares For US$1.2 Million Upon Exercise Of Warrants 255
Ablynx Completes Private Placement Of Shares For US$41 Million 256
KaloBios Pharma Completes IPO For US$70 Million 257
Debt Offering 259
Sanofi Prices Public Offering of 3.375% Notes Due 2023 for USD1 Billion 259
Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 260
Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 261
Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.54 Billion 262
Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 263
Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 264
Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 265
Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 266
Sanofi Prices Public Offering of Notes Due 2027 for USD1.3 Billion 267
Sanofi Prices Public Offering of Notes Due 2020 for USD1.1 Billion 268
Sanofi Prices Public Offering of Notes Due 2022 for USD948 Million 269
Sanofi Raises USD684.07 million in Public Offering of Notes Due 2024 270
Sanofi Raises USD570 million in Public Offering of Notes Due 2019 271
Sanofi Raises USD798.08 million in Public Offering of Notes Due 2028 272
Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 273
Sanofi Prices Public Offering of 0.875% Notes Due 2021 for USD566.4 Million 274
Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 275
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 276
Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 277
Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 278
Sanofi Prices Public Offering of Floating Rate Notes Due 2018 for USD984 Million 279
Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 280
Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 281
Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 282
Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 284
Asset Transactions 285
Recipharm to Acquire CMO Business from Sanofi 285
Partner Therapeutics Acquires Rights of Leukine from Sanofi 287
MicroPharm Acquires Equine Antivenom Immunoglobulin Products from Sanofi Pasteur 288
Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 289
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 291
Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 292
Impact Biomedicines Acquires Rights for Fedratinib from Sanofi 294
Icagen Acquires Arizona Research Facility from Sanofi 295
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 296
Validus Pharma and Wood Creek Capital Acquire US Rights to Several Product Lines from Sanofi-Aventis US 297
Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 298
Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 299
Ferring Pharma Acquires Ddavp from Sanofi 300
Prollenium Medical Acquires Rights to Alyria Skincare Portfolio from Sanofi Consumer Health 301
Admedus Acquires Manufacturing Facility From Genzyme Australasia 302
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 303
Covis Pharma To Acquire US Commercialization Rights For Five Products From sanofi-aventis 304
Wood Pharma Acquires Production Facility In Hlohovec From Zentiva 306
Fareva Acquires API Production Site from Sanofi 307
Ubichem Pharma Services Acquires Manufacturing Facility In Hungary From Sanofi 308
Acquisition 309
Sanofi Acquires Ablynx for USD4.85 Billion 309
Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 311
Zentiva to Acquire Additional 18.32% Stake in Sicomed for USD70.9 Million 313
Sanofi Acquires Protein Sciences 314
Bioverativ Therapeutics Acquires True North Therapeutics 315
Eurapharma Plans to Acquire 51% Stake in Maphar 316
Medis Labs Acquires Winthrop Pharma from Sanofi 317
Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 318
Sanofi May Acquire BioMarin Pharma 319
Sanofi to Sell 4.76% Stake in Nichi-iko Pharma 320
Sanofi May Acquire PTC Therapeutics 321
Sanofi-Synthelabo Acquires 20% Stake in Apollo Sugar Clinics for USD14.6 Million 322
Dubai Investments Divests 66% Stake in Globalpharma 323
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 324
Sofinnova Divests Its Stake In Ablynx For US$29.4 Million 325
Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 326
Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 327
LOreal Plans To Sell Its Stake In Sanofi 328
Sanofi Plans To Acquire Consumer Healthcare Products Company In China 329
Sanofi Completes Acquisition Of Genfar, Generic Drugs Manufacturer 330
Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 331
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 332
Sanofi-Aventis Israel To Acquire Consumer Healthcare Products Company 334
Evotec Acquires DeveloGen For USD18 Million 335
Sanofi - Key Competitors 337
Sanofi - Key Employees 338
Sanofi - Locations And Subsidiaries 340
Head Office 340
Other Locations & Subsidiaries 340
Joint Venture 354
Recent Developments 355
Financial Announcements 355
Nov 02, 2017: Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed 355
Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 362
Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 368
Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 370
Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 376
Corporate Communications 384
Jun 19, 2018: Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer 384
May 08, 2018: Sanofi Announces Appointment of Mr. Charles Billard as Chief Financial Officer and Key Managerial Personnel 385
Apr 24, 2018: Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 386
Jan 19, 2018: Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee 387
Apr 12, 2017: Sanofi appoints Nikhilesh Kalra to lead Consumer Healthcare business for India and South Asia 388
Apr 11, 2017: Sanofi Announces Pre-quarterly Results Communication 389
Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK 391
Government and Public Interest 392
Dec 05, 2017: Sanofi and IBM Watson Health real-world analysis showed that individuals not achieving control on basal insulin within 12 months 392
Sep 14, 2017: Insulin therapy initially declined and delayed by an average of 2 years 393
Product News 394
Dec 12, 2017: Striving to Defeat Dengue with Effective Vaccines 394
Dec 06, 2017: Sanofi continues to seek clinical trial waiver in India for controversial dengue vaccine 396
10/17/2017: Sanofi Genzyme Presents Abstracts on Lemtrada at ECTRIMS-ACTRIMS 397
09/11/2017: Sanofi Launches Combiflam ICYHOT Pain Relief Topical in India 399
08/01/2017: Prince Edward Island includes LEMTRADA (alemtuzumab) on provincial drug program for eligible patients 400
04/23/2018: Treatment Effects Maintained over Seven Years in Patients with Relapsing Remitting Multiple Sclerosis Who Received Lemtrada (alemtuzumab) in Clinical Trials 401
04/19/2018: Sanofi Genzymes Multiple Sclerosis Data to Be Featured at AAN 402
04/11/2017: Sanofi Genzyme to present data on Lemtrada (alemtuzumab) at AAN 404
02/06/2018: British Columbia includes (Pr)LEMTRADA (alemtuzumab) on provincial drug program for eligible patients 406
Clinical Trials 407
Oct 27, 2017: Treatment Effects Maintained Over Five Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzymes Lemtrada (alemtuzumab) in Extension Study After Switching from Interferon Beta-1a 407
Apr 25, 2017: New Investigational Data on Six-Year Efficacy of Sanofi Genzymes Lemtrada (alemtuzumab) in Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented at AAN 409
Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491 411
Jan 12, 2017: Protein Sciences Zika Vaccine Shows Good Results in Preclinical Testing 412
Other Significant Developments 413
May 14, 2018: Sanofi: Accelerating Future Breakthroughs Through Clinical Trials 413
Apr 27, 2018: Sanofi: First-quarter 2018 Business EPS up 1.4% at CER 415
Feb 27, 2018: Sanofi Adopts Genedata Selector to Optimize Strain Development 422
Feb 07, 2018: Sanofi Delivers 2017 Business EPS in line with Guidance 423
Mar 02, 2017: Sanofi Launches Digital Clinical Trials to Improve Recruitment and Reduce Trial Times 425
Jan 09, 2017: MannKind Receives $30.6 Million From Sanofi 426
Appendix 427
Methodology 427
About GlobalData 427
Contact Us 427
Disclaimer 427

List Of Tables

List of Tables
Sanofi, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16
Sanofi, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 17
Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18
Sanofi, Deals By Therapy Area, 2012 to YTD 2018 19
Sanofi, Medical Devices Deals, 2012 to YTD 2018 21
Sanofi, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 22
Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 36
Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 37
Genzyme Acquires Caprelsa from AstraZeneca 39
Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 40
Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 41
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For US$98.5 Million 42
Sanofi To Acquire Generic Drugs Rights From Medreich India 43
Thermalin Raises Funds through First Tranche of Series A Preferred Financing 44
True North Therapeutics Raises USD45 Million in Series D Financing 45
True North Therapeutics Raises USD40 Million in Series C Financing 46
Portal Instruments Raises USD25 Million in Series B Financing 48
MyoKardia Raises USD46 Million in Series B Financing 49
True North Therapeutics Raises USD35 Million in Series B Financing 50
Portal Instruments Raises USD11 Million in Series A Venture Financing 51
True North Therapeutics Raises USD22 Million in Series A Venture Financing 52
Edimer Pharma Raises US$18 Million In Series B Financing 54
Ultragenyx Pharma Raises US$75 Million In Series B Financing 56
Kahr Medical To Raise US$2.5 Million In Venture Financing 58
Warp Drive Bio Raises US$75 Million In Series A Venture Financing 60
Advent International to Acquire Zentiva from Sanofi for USD2.37 Billion 61
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 63
Sanofi Plans to Sell Portfolio of Drugs 65
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 66
Ablynx Exercises Option for Licensing Agreement with Vectura 67
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 68
Evotec Enters into R&D Agreement with Sanofi 69
Translate Bio to Enter into Agreement with Sanofi Pasteur 70
Innovative Targeting Solutions Enters into Research Agreement with Sanofi 71
Applied BioMath Enters into Partnership with Sanofi for Systems Pharmacology Modeling 72
AnaBios and Sanofi Enter into Agreement 73
Iontas Enters into Agreement with Sanofi 74
Alnylam Pharma and Sanofi to Enter into Agreement 75
Sanofi to Form Partnership with Groupe Saidal and Pasteur Institute of Algeria 76
Berg Enters into Research Agreement with Sanofi 77
Applied BioMath Enters into Partnership with Sanofi 78
Sanofi Enters into Agreement with Max Delbruck Center, Charite and Berlin Institute of Health 79
Thermalin Enters into Partnership with Sanofi 80
Bioverativ Enters into Research Agreement with Bicycle Therapeutics 81
Axxam Enters into Research Agreement with Sanofi 82
AbCellera Biologics Enters into Partnership with Sanofi Pasteur 83
Ex Scientia Enters into Research and Option Agreement with Sanofi 84
Sanofi Enters into Research Agreement with Exscientia 85
Sanofi Enters into Co-Development Agreement with MedImmune 86
Sanofi Enters into Co-Promotion Agreement with Yakult Honsha 87
Enteris BioPharma Enters into Agreement with Sanofi 88
Sanofi Enters into Agreement with JHL Biotech 89
Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 90
Mymetics Enters into Research Agreement with Sanofi 91
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 92
Myriad Enters into Agreement with Sanofi 93
Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 94
Protein Sciences Enters into Agreement with Biomedical Advanced Research and Development Authority 95
Sanofi Pasteur Expands R&D Agreement with Walter Reed Army Institute of Research and Bio Manguinhos and Fiocruz 96
Sanofi Enters into Co-Development Agreement with Joslin Diabetes Center 97
Sanofi Enters into Research Agreement with Ksilink 98
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 99
Recursion Pharma Enters into Research Agreement with Genzyme 100
Hummingbird Bioscience Enters into Partnership with Sanofi 101
Protein Sciences Enters into Co-Development Agreement with Sinergium Biotech and Mundo Sano 102
Sanofi Enters into Research Agreement with DiCE Molecules 103
Sanofi Enters into Drug Discovery Agreement with University of Tokyo 104
Sanofi and Juvenile Diabetes Research Foundation Partner with Four Research Organizations 105
Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 107
X-Chem Enters into Agreement with Sanofi 108
Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 109
Sanofi Pasteur Enters into Partnership with Infectious Disease Research Institute 110
PeptiDream Enters into Discovery Agreement with Sanofi 111
Evotec Enters into Research Agreement with Sanofi 112
Regeneron Pharma Amends Co-Development Agreement with Sanofi 113
Sanofi-Aventis Extends Agreement with Medicines For Malaria Venture 115
Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 116
Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 117
NeuroVive Pharma Enters into Co-Development Agreement with Sanofi 118
Ablynx Enters into Research Agreement with Genzyme 119
Innate Pharma Enters into Agreement with Sanofi for Next Generation Antibody-Drug Conjugates 120
VBI Vaccines Enters into Research Agreement with Sanofi Pasteur 121
Schrodinger Enters into Agreement with Sanofi 122
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 123
Regeneron Pharma Amends Co-Development Agreement with Sanofi 124
Voyager Therapeutics Enters into Development Agreement with Genzyme 125
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 126
Sanofi Enters into Research Agreement with Vect-Horus 127
Catalent Pharma Enters into Co-Development Agreement with Sanofi-Aventis 128
Evotec to Enter into Co-Development Agreement with Sanofi 129
Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 131
Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 132
Apollo Hospitals Plans to Form Joint Venture with Sanofi 133
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 134
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 135
Sanofi Extends its Co-Development Agreement with MyoKardia 136
Sanofi Enters into Distribution Agreement with Emcure for Oncology Drugs 137
Sanofi Enters into Co-Development Agreement with Medtronic 138
Sanofi Enters into Drug Discovery Agreement with CQDM 139
Dubai Investments to Enter into Agreement with Sanofi to Promote Generics 140
Genzyme Enters Into Research Agreement With Cleveland Clinic 141
Taiwan Liposome and Ablynx Enter into Research Agreement 142
Sanofi Enters Into Agreement With UCB For Drug Discovery 143
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 144
Smartox Biotech Enters Into Research Agreement With Sanofi For Drug Discovery 146
Sanofi Pasteur Enters into Agreement with University of Melbourne to Develop Human Vaccines 147
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 148
Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 149
Gubra Enters into Research Collaboration with Sanofi 150
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 151
NextBio Enters Into Agreement With Sanofi For Translational Medicine 152
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 153
Sanofi Pasteur Enters Into Co-Development Agreement With Xiamen University For Universal Flu Vaccine 154
Oncodesign Enters Into Research Agreement With Sanofi 155
Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 156
PharmAbcine Enters Into Research Agreement With Sanofi For Antibody Drug Discovery 157
Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 158
Y-Biologics Expands Agreement with Sanofi 159
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 160
LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea For Zemiglo 161
Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 162
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 163
China State Institute of Pharma Enters Into Research Agreement With Sanofi 164
Sanofi Enters Into Research Agreement With Charite- Universitatsmedizin For Treatment Of Diabetes 165
Sanofi Enters Into Research Agreement With TB Alliance To Advance Treatments For Tuberculosis 166
Sanofi Enters Into Research Agreement With Oncodesign 167
LegoChem Biosciences Enters into Research Agreement with Sanofi 168
Sanofi Enters Into Research Agreement With Brigham and Womens Hospital 169
Regulus Therapeutics Expands Agreement With Sanofi-Aventis 170
Sanofi Forms Joint Venture With Hisamitsu Pharma For OTC Medications 171
Sanofi Enters Into Co-Development Agreement With Joslin Diabetes Center For Novel Diabetes Drugs 172
Sanofi Enters Into Research Agreement With Bioneer 173
Sanofi Enters Into Co-Development Agreement With Alfresa For Antiepileptic Drug 174
Sanofi Enters into Co-Development Agreement with CNRH, INRA, ASL and 3iNature 175
Centre For Genomic Regulation Enters Into Research Agreement With Sanofi 176
Centre de Regulacio Genomica Enters Into Research Agreement With Sanofi 177
Sanofi Pasteur India Enters Into Co-Marketing Agreement With Emcure Pharma For Rabies Vaccine 178
University of California Enters Into Research Agreement With Sanofi 179
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 180
Sanofi Japan and Genzyme Japan Merge 181
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 182
Sanofi Pasteur Enters into Licensing Agreement with SK Chemicals 183
Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 184
Sanofi to Enter into Licensing Agreement with Principia Biopharma 185
Sanofi Enters into Licensing Agreement with Ablynx 186
Sanofi Enters into Licensing Agreement with ImmuNext 187
Sanofi Enters into Licensing Agreement with Hanmi Pharma 188
Avanzcare Enters into Licensing Agreement with Protein Sciences 189
uniQure Enters into Licensing Agreement with Protein Sciences 190
Sanofi Enters into Licensing Agreement with Affilogic 191
IXALTIS Enters into Licensing Agreement with Sanofi 192
Orygen Biotecnologia Enters into Licensing Agreement with Protein Sciences for Flublok 193
Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 194
Sanofi Enters into Licensing Agreement with Innate Pharma 195
Novo Nordisk Enters into Licensing Agreement with Ablynx 196
Sanofi Amends Licensing Agreement with Lexicon Pharma 197
Sanofi Enters into Licensing Agreement with BioNTech 199
Sanofi Enters into Licensing Agreement with Ligand Pharma 200
Zai Lab Enters into Licensing Agreement with Sanofi 201
Taisho Pharma Enters into Licensing Agreement with Ablynx 202
Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 203
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 204
Protein Sciences Enters into Licensing Agreement with Liomont for Flublok and Panblok 205
Sanofi Enters into Licensing Agreement with Immune Design 206
CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 207
Sanofi Enters into Licensing Agreement with Eli Lilly for Cialis 208
Oxford BioMedica Amends Licensing Agreement With Sanofi 210
Merck Expands Licensing Agreement with Ablynx 211
Ablynx Enters Into Licensing Agreement With Eddingpharm 213
Regulus Therapeutics Amends Licensing Agreement With Sanofi 215
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 216
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 217
Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 218
Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 219
Sanofi Pasteur Expands Licensing Agreement With Vivalis 220
Sanofi Enters into Licensing Agreement with Warp Drive Bio 221
Sanofi Enters into Licensing Agreement with MAB Discovery 222
Sanofi Enters into Licensing Agreement with Lead Pharma for Autoimmune Diseases 223
ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 224
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 225
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 226
uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 227
Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 228
Sanofi Pasteur Enters Into Licensing Agreement With ORGANOBALANCE For Saccharomyces Cerevisiae 229
Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 230
Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 231
Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 232
Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 233
Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 235
Ablynx Amends Private Placement of Shares 236
Ablynx Raises USD1.05 Million Through Exercise of Warrants 238
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 239
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 240
Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 241
JHL Biotech Raises USD80 Million in Private Placement of Shares 242
Ablynx Raises USD82.6 Million in Private Placement of Shares 243
Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 245
Ablynx Raises USD1.4 Million upon Exercise of Warrants 246
Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 247
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 248
X4 Pharma Spin Off from Sanofi 249
Protein Sciences Raises USD0.6 Million in Private Placement of Shares 250
Ablynx Raises USD57 Million in Private Placement of Shares 251
Regulus Therapeutics Completes Private Placement Of Shares For US$10 Million 253
Protein Sciences Raises USD8.4 Million in Private Placement of Shares 254
Ablynx Completes Private Placement Of Shares For US$1.2 Million Upon Exercise Of Warrants 255
Ablynx Completes Private Placement Of Shares For US$41 Million 256
KaloBios Pharma Completes IPO For US$70 Million 257
Sanofi Prices Public Offering of 3.375% Notes Due 2023 for USD1 Billion 259
Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 260
Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 261
Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.54 Billion 262
Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 263
Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 264
Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 265
Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 266
Sanofi Prices Public Offering of Notes Due 2027 for USD1.3 Billion 267
Sanofi Prices Public Offering of Notes Due 2020 for USD1.1 Billion 268
Sanofi Prices Public Offering of Notes Due 2022 for USD948 Million 269
Sanofi Raises USD684.07 million in Public Offering of Notes Due 2024 270
Sanofi Raises USD570 million in Public Offering of Notes Due 2019 271
Sanofi Raises USD798.08 million in Public Offering of Notes Due 2028 272
Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 273
Sanofi Prices Public Offering of 0.875% Notes Due 2021 for USD566.4 Million 274
Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 275
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 276
Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 277
Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 278
Sanofi Prices Public Offering of Floating Rate Notes Due 2018 for USD984 Million 279
Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 280
Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 281
Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 282
Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 284
Recipharm to Acquire CMO Business from Sanofi 285
Partner Therapeutics Acquires Rights of Leukine from Sanofi 287
MicroPharm Acquires Equine Antivenom Immunoglobulin Products from Sanofi Pasteur 288
Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 289
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 291
Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 292
Impact Biomedicines Acquires Rights for Fedratinib from Sanofi 294
Icagen Acquires Arizona Research Facility from Sanofi 295
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 296
Validus Pharma and Wood Creek Capital Acquire US Rights to Several Product Lines from Sanofi-Aventis US 297
Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 298
Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 299
Ferring Pharma Acquires Ddavp from Sanofi 300
Prollenium Medical Acquires Rights to Alyria Skincare Portfolio from Sanofi Consumer Health 301
Admedus Acquires Manufacturing Facility From Genzyme Australasia 302
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 303
Covis Pharma To Acquire US Commercialization Rights For Five Products From sanofi-aventis 304
Wood Pharma Acquires Production Facility In Hlohovec From Zentiva 306
Fareva Acquires API Production Site from Sanofi 307
Ubichem Pharma Services Acquires Manufacturing Facility In Hungary From Sanofi 308
Sanofi Acquires Ablynx for USD4.85 Billion 309
Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 311
Zentiva to Acquire Additional 18.32% Stake in Sicomed for USD70.9 Million 313
Sanofi Acquires Protein Sciences 314
Bioverativ Therapeutics Acquires True North Therapeutics 315
Eurapharma Plans to Acquire 51% Stake in Maphar 316
Medis Labs Acquires Winthrop Pharma from Sanofi 317
Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 318
Sanofi May Acquire BioMarin Pharma 319
Sanofi to Sell 4.76% Stake in Nichi-iko Pharma 320
Sanofi May Acquire PTC Therapeutics 321
Sanofi-Synthelabo Acquires 20% Stake in Apollo Sugar Clinics for USD14.6 Million 322
Dubai Investments Divests 66% Stake in Globalpharma 323
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 324
Sofinnova Divests Its Stake In Ablynx For US$29.4 Million 325
Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 326
Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 327
LOreal Plans To Sell Its Stake In Sanofi 328
Sanofi Plans To Acquire Consumer Healthcare Products Company In China 329
Sanofi Completes Acquisition Of Genfar, Generic Drugs Manufacturer 330
Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 331
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 332
Sanofi-Aventis Israel To Acquire Consumer Healthcare Products Company 334
Evotec Acquires DeveloGen For USD18 Million 335
Sanofi, Key Competitors 337
Sanofi, Key Employees 338
Sanofi, Subsidiaries 340
Sanofi, Joint Venture 354

List Of Figures

List of Figures
Sanofi, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16
Sanofi, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 17
Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18
Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 19
Sanofi, Medical Devices Deals, 2012 to YTD 2018 21

Sanofi: Performance, Capabilities, Goals and Strategies in the Global Pharmaceutical Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950 View Report

Sanofi SA - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Sanofi SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Sanofi SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350 View Report

Sanofi (SAN) - Strategic SWOT Analysis Review

Sanofi (SAN) - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on

USD 125 View Report

Sanofi (SAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sanofi is a healthcare company that researches, develops, manufactures and markets a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available